Janssen
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Guardant Health Liquid Biopsy CDx Gets Japanese Regulatory Approval for Janssen Lung Cancer Drug
Patients with inoperable or recurrent NSCLC and EGFR exon 20 insertion mutations may be eligible for Janssen Pharmaceutical's amivantamab-vmjw.
FDA Approves FoundationOne Liquid CDx to Select BRCA-Mutated mCRPC Patients for Janssen's Akeega
The FDA expanded the label to include the blood-based sequencing test as well as the tissue-based CDx, which was already approved to select patients for Akeega.
Gilead, Arcellx Outline Plans for Phase III Anito-Cel Multiple Myeloma Trial
The partners will compare the activity of the BCMA-directed autologous CAR T-cell therapy against standard treatment in refractory patients.
Janssen, Legend Biotech's Carvykti Nets EU Approval in Early-Line Multiple Myeloma
The approval makes the CAR T-cell therapy available to advanced multiple myeloma patients earlier in the course of their treatment.